Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 4.40
BCRX's Cash to Debt is ranked higher than
70% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: 20.79 vs. BCRX: 4.40 )
BCRX' s 10-Year Cash to Debt Range
Min: 0.94   Max: 11087.67
Current: 4.4

0.94
11087.67
Equity to Asset 0.64
BCRX's Equity to Asset is ranked higher than
72% of the 766 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. BCRX: 0.64 )
BCRX' s 10-Year Equity to Asset Range
Min: -0.23   Max: 0.98
Current: 0.64

-0.23
0.98
F-Score: 6
Z-Score: 4.80
M-Score: -2.88
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -180.75
BCRX's Operating margin (%) is ranked higher than
65% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -65.07 vs. BCRX: -180.75 )
BCRX' s 10-Year Operating margin (%) Range
Min: -17879.61   Max: -18.42
Current: -180.75

-17879.61
-18.42
Net-margin (%) -213.74
BCRX's Net-margin (%) is ranked higher than
63% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -70.66 vs. BCRX: -213.74 )
BCRX' s 10-Year Net-margin (%) Range
Min: -17170.39   Max: -18.03
Current: -213.74

-17170.39
-18.03
ROE (%) -246.23
BCRX's ROE (%) is ranked higher than
65% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -21.70 vs. BCRX: -246.23 )
BCRX' s 10-Year ROE (%) Range
Min: -544.61   Max: -8.43
Current: -246.23

-544.61
-8.43
ROA (%) -58.37
BCRX's ROA (%) is ranked higher than
68% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: -18.92 vs. BCRX: -58.37 )
BCRX' s 10-Year ROA (%) Range
Min: -67.46   Max: -7.68
Current: -58.37

-67.46
-7.68
ROC (Joel Greenblatt) (%) -10318.65
BCRX's ROC (Joel Greenblatt) (%) is ranked higher than
52% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: -215.73 vs. BCRX: -10318.65 )
BCRX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -6910.46   Max: -43.48
Current: -10318.65

-6910.46
-43.48
Revenue Growth (%) -39.50
BCRX's Revenue Growth (%) is ranked higher than
61% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. BCRX: -39.50 )
BCRX' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 430.1
Current: -39.5

0
430.1
EBITDA Growth (%) -14.10
BCRX's EBITDA Growth (%) is ranked higher than
70% of the 626 Companies
in the Global Biotechnology industry.

( Industry Median: -8.10 vs. BCRX: -14.10 )
BCRX' s 10-Year EBITDA Growth (%) Range
Min: -41.9   Max: 64.5
Current: -14.1

-41.9
64.5
EPS Growth (%) -10.20
BCRX's EPS Growth (%) is ranked higher than
75% of the 645 Companies
in the Global Biotechnology industry.

( Industry Median: -10.20 vs. BCRX: -10.20 )
BCRX' s 10-Year EPS Growth (%) Range
Min: -38.4   Max: 52.9
Current: -10.2

-38.4
52.9
» BCRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2012

BCRX Guru Trades in Q3 2012

Jim Simons 70,129 sh (-52.93%)
» More
Q4 2012

BCRX Guru Trades in Q4 2012

Jim Simons Sold Out
» More
Q1 2014

BCRX Guru Trades in Q1 2014

George Soros 59,700 sh (New)
Jim Simons 90,514 sh (New)
» More
Q2 2014

BCRX Guru Trades in Q2 2014

Jim Simons Sold Out
George Soros Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with BCRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2014-06-30 Sold Out 0.01%$7.37 - $12.52 $ 10.7111%0
George Soros 2014-03-31 New Buy0.01%$7.6 - $12.83 $ 10.711%59700
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 7.14
BCRX's P/B is ranked higher than
69% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 6.41 vs. BCRX: 7.14 )
BCRX' s 10-Year P/B Range
Min: 1.04   Max: 122.5
Current: 7.14

1.04
122.5
P/S 35.70
BCRX's P/S is ranked higher than
68% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 20.67 vs. BCRX: 35.70 )
BCRX' s 10-Year P/S Range
Min: 0.73   Max: 1000
Current: 35.7

0.73
1000
EV-to-EBIT -18.87
BCRX's EV-to-EBIT is ranked higher than
65% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. BCRX: -18.87 )
BCRX' s 10-Year EV-to-EBIT Range
Min: 0.3   Max: 1473.6
Current: -18.87

0.3
1473.6
Current Ratio 3.08
BCRX's Current Ratio is ranked higher than
67% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 4.31 vs. BCRX: 3.08 )
BCRX' s 10-Year Current Ratio Range
Min: 2.01   Max: 39.53
Current: 3.08

2.01
39.53
Quick Ratio 3.08
BCRX's Quick Ratio is ranked higher than
69% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 3.96 vs. BCRX: 3.08 )
BCRX' s 10-Year Quick Ratio Range
Min: 2   Max: 39.53
Current: 3.08

2
39.53

Valuation & Return

vs
industry
vs
history
Price/Net Cash 7.99
BCRX's Price/Net Cash is ranked higher than
87% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 190.00 vs. BCRX: 7.99 )
BCRX' s 10-Year Price/Net Cash Range
Min: 0.61   Max: 315
Current: 7.99

0.61
315
Price/Net Current Asset Value 7.93
BCRX's Price/Net Current Asset Value is ranked higher than
87% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 79.32 vs. BCRX: 7.93 )
BCRX' s 10-Year Price/Net Current Asset Value Range
Min: 0.61   Max: 191
Current: 7.93

0.61
191
Price/Tangible Book 7.14
BCRX's Price/Tangible Book is ranked higher than
75% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9.62 vs. BCRX: 7.14 )
BCRX' s 10-Year Price/Tangible Book Range
Min: 0.33   Max: 121.33
Current: 7.14

0.33
121.33
Price/Median PS Value 4.68
BCRX's Price/Median PS Value is ranked higher than
67% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 1.97 vs. BCRX: 4.68 )
BCRX' s 10-Year Price/Median PS Value Range
Min: 0.12   Max: 122.25
Current: 4.68

0.12
122.25
Earnings Yield (Greenblatt) 47.80
BCRX's Earnings Yield (Greenblatt) is ranked higher than
91% of the 469 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. BCRX: 47.80 )
BCRX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 355.1
Current: 47.8

0.1
355.1
Forward Rate of Return (Yacktman) 11.96
BCRX's Forward Rate of Return (Yacktman) is ranked higher than
94% of the 757 Companies
in the Global Biotechnology industry.

( Industry Median: -10.00 vs. BCRX: 11.96 )
BCRX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -54.7   Max: -27.4
Current: 11.96

-54.7
-27.4

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:BO1.Germany
BioCryst Pharmaceuticals is a Delaware Corporation originally founded in 1986. The Company is a biotechnology company that designs, optimizes and develops novel drugs that block key enzymes involved in cancer, viral infections and autoimmune diseases. BioCryst integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-based drug design. Structure-guided drug design is a drug discovery approach by which it designs synthetic compounds from detailed structural knowledge of the active sites of enzyme targets associated with particular diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and advanced chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. The Company has two Purine Nucleoside Phosphorylase (PNP ) inhibitors that are in development, ulodesine for the treatment of gout and forodesine for the treatment of hematological malignancies. PNP is a purine salvage pathway enzyme. Low doses of PNP inhibitors could be useful in reducing serum uric acid for the treatment of gout, while high doses of PNP inhibitors could be useful in the treatment of hematological malignancies. The FDA regulates the pharmaceutical and biotechnology industries in the U.S., and its drug candidates are subject to extensive and rigorous domestic government regulations prior to commercialization.
» More Articles for BCRX

Headlines

Articles On GuruFocus.com
comment on BCRX Mar 02 2013 
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 15 2011 
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-K/A) Jan 19 2011 
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 08 2010 
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 06 2010 
BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 2,500 Shares Aug 06 2010 
BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 1,250 Shares Jun 04 2010 
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q) May 07 2010 
BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 1,250 Shares May 05 2010 
BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 38,553 Shares Apr 30 2010 


More From Other Websites
Nasdaq stocks posting largest percentage increases Sep 19 2014
The Dire Need For A Rapid Diagnostic Ebola Test In West Africa Sep 18 2014
BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other... Sep 18 2014
12:08 pm BioCryst Pharm receives additional NIAID funding for manufacture and development of BCX4430... Sep 18 2014
BioCryst Receives Additional NIAID Funding for Manufacture and Development of BCX4430 to Treat... Sep 18 2014
[$$] Who Is Working on Ebola? Sep 18 2014
Containing Ebola Outbreak Requires American Leadership Sep 16 2014
Momentum Stocks Showing Weakness Sep 15 2014
Gates Foundation Commits $50 Million To Ebola Containment Efforts Sep 10 2014
Trade Ebola Stocks? Sure, But Don't Bet on Big Business Opportunity Sep 10 2014
BioCryst Announces RAPIVAB(TM) Trial Results for the Treatment of Influenza at the ICAAC 2014... Sep 06 2014
WHO Ebola Drug Panel: Use Survivor Serum To Treat Ebola Victims Sep 05 2014
BioCryst Pharmaceuticals, Inc. Sinks; WHO Notes Ebola Safety Data Unavailable Sep 05 2014
BioCryst Participates in World Health Organization Consultation on Potential Ebola Therapies Sep 04 2014
BioCryst to Present at Rodman & Renshaw Conference Sep 03 2014
BioCryst's Ebola Candidate Moving to Efficacy Study Soon Sep 02 2014
BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure Sep 02 2014
BioCryst to Present Peramivir Trial Results for the Treatment of Influenza at the ICAAC 2014 Meeting Sep 02 2014
BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other... Aug 29 2014
BioCryst to Launch NHP Ebola Drug Safety, Efficacy Studies 'Within Weeks' Aug 29 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK